Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
Rakesh Awasthi, Lida Pacaud, Edward Waldron, Constantine S Tam, Ulrich Jager, Peter Borchmann, Samantha Jaglowski, Stephen Ronan Foley, Koen van Besien, Nina D Wagner-Johnston, Marie Jose Kersten, Stephen J Schuster, Gilles Salles, Richard T Maziarz, Ozlem Anak, Christopher del Corral, Jufen Chu, Irina Gershgorin, Iulian Pruteanu-Malinici, Abhijit Chakraborty Show all
Blood Advances | AMER SOC HEMATOLOGY | Published : 2020
This study and writing assistance were supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Medical writing assistance was provided by Beena John and Rozena Varghese, CMPP, of C4 MedSolutions, LLC (Yardley, PA), a CHC Group company.